Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00661609 · ClinicalTrials.gov registry record · Phase 2
A Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) in Advanced Bladder Cancer
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 54
- Enrollment target
NCT00661609 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 54 participants.
The verdict
NCT00661609, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 54 participants
- Enrollment target
Study Summary
The purpose of this Phase II study is to determine if AZD4877, an experimental drug that is a novel anti-mitotic agent (Eg5 or Kinesin Spindle Protein inhibitor that interferes with tumor cell division leading to tumor growth), can reduce tumor sizes in patients with bladder cancer
Interventions
- DRUG AZD4877
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2008-05 |
| Est. Completion | 2009-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00661609
The ClinicalTrials.gov registry entry for NCT00661609 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AZD4877 is the first listed.
NCT00661609 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00661609 about?
NCT00661609 is a clinical study titled "A Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) in Advanced Bladder Cancer". The purpose of this Phase II study is to determine if AZD4877, an experimental drug that is a novel anti-mitotic agent (Eg5 or Kinesin Spindle Protein inhibitor that interferes with tumor cell division leading to tumor growth), can reduce tumor sizes in patients with bladder cancer
What is the current status of trial NCT00661609?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 54 participants. The study started on 2008-05. Estimated completion is 2009-12.
What interventions are being tested in trial NCT00661609?
The interventions under investigation include: AZD4877 (DRUG).
Who is sponsoring clinical trial NCT00661609?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.